HALO
Halozyme Therapeutics Inc.

4,836
Mkt Cap
$8.02B
Volume
11.66M
52W High
$79.50
52W Low
$42.01
PE Ratio
14.34
HALO Fundamentals
Price
$68.24
Prev Close
$68.39
Open
$69.02
50D MA
$70.66
Beta
0.68
Avg. Volume
1.93M
EPS (Annual)
$3.43
P/B
15.91
Rev/Employee
$2.9M
Loading...
Loading...
News
all
press releases
Halozyme Therapeutics (NASDAQ:HALO) Sees Large Volume Increase - Still a Buy?
Halozyme Therapeutics (NASDAQ:HALO) Sees Large Volume Increase - Here's What Happened...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
Envestnet Asset Management Inc. Reduces Stake in Halozyme Therapeutics, Inc. $HALO
Envestnet Asset Management Inc. lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 11.2% in the 2nd quarter, according to its most recent disclosure with the...
MarketBeat·17h ago
News Placeholder
Halozyme Therapeutics (NASDAQ:HALO) Cut to Buy at Wall Street Zen
Wall Street Zen cut Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Saturday...
MarketBeat·18h ago
News Placeholder
FDA Approved DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma
FDA Approved DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma FDA Approved DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma PR Newswire SAN...
PR Newswire·2d ago
News Placeholder
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 Halozyme Therapeutics...
PR Newswire·2d ago
News Placeholder
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
Zacks·4d ago
News Placeholder
Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·5d ago
News Placeholder
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +5.52% and +5.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL...
PR Newswire·5d ago
News Placeholder
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·12d ago

Latest HALO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.